Literature DB >> 1379443

CD59: a molecule involved in antigen presentation as well as downregulation of membrane attack complex.

G T Venneker1, S S Asghar.   

Abstract

CD59 is a recently discovered complement (C) regulatory protein. Three activities of CD59 have been recognized so far. It can downregulate the activation of the C cascade at membrane attack complex formation stage, it participates in T-cell rosette formation with erythrocytes and appears to be necessary for T-cell activation. CD59 is broadly distributed on cells of various organs and this is compatible with its function of protecting cells and tissues from incidentally activated autologous C. CD59 is encoded by a single gene residing on chromosome 11. The entire sequence of CD59 cDNA is known, from which the amino acid structure of CD59 has been deduced. Mature CD59 is made up of 103 amino acids. It has two potential N-glycosylation sites. Carbohydrate constitutes about 20% of the molecular mass of CD59. The protein part of the molecule is covalently linked to an oligosaccharide which, in turn, is glycosydically linked to phosphatidylinositol (PI). CD59 is anchored to the cells via PI moiety. The fine structure of the PI anchor of CD59 has not yet been established. Decreased expression of CD59 has been shown in two diseases. In paroxysmal nocturnal hemoglobinuria, erythrocytes (type III) lacking CD59 (and other PI proteins) have susceptibility to lysis by membrane attack complex. In psoriasis, expression of CD59 (and CD55) is drastically decreased in psoriatic lesions, presumably due to PI cleavage involving signal transduction mechanism(s) leading to increased proliferation of various cell types in lesional skin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379443

Source DB:  PubMed          Journal:  Exp Clin Immunogenet        ISSN: 0254-9670


  7 in total

Review 1.  Is rheumatoid arthritis a failure of B cell death in synovium?

Authors:  J C Edwards; J Cambridge
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

Review 2.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

3.  Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.

Authors:  Ellinor I B Peerschke; Biree Andemariam; Wei Yin; James B Bussel
Journal:  Br J Haematol       Date:  2009-11-19       Impact factor: 6.998

4.  PI3K/Akt pathway restricts epithelial adhesion of Dr + Escherichia coli by down-regulating the expression of decay accelerating factor.

Authors:  Manu Banadakoppa; Pawel Goluszko; Daniel Liebenthal; Bogdan J Nowicki; Stella Nowicki; Chandra Yallampalli
Journal:  Exp Biol Med (Maywood)       Date:  2014-03-05

5.  Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation.

Authors:  C Sugimori; E Padron; G Caceres; K Shain; L Sokol; L Zhang; R Tiu; C L O'Keefe; M Afable; M Clemente; J M Lee; J P Maciejewski; A F List; P K Epling-Burnette; D J Araten
Journal:  Blood Cancer J       Date:  2012-03-23       Impact factor: 11.037

6.  Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium.

Authors:  K Koretz; S Brüderlein; C Henne; P Möller
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

7.  Immunoprofiling Reveals Novel Mast Cell Receptors and the Continuous Nature of Human Lung Mast Cell Heterogeneity.

Authors:  Elin Rönnberg; Daryl Zhong Hao Boey; Avinash Ravindran; Jesper Säfholm; Ann-Charlotte Orre; Mamdoh Al-Ameri; Mikael Adner; Sven-Erik Dahlén; Joakim S Dahlin; Gunnar Nilsson
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.